Skip to main content

Table 1 HER2 status generally correlates with DCIS size, with HER2-positive DCIS often being larger than HER2-negative DCIS in most studies

From: Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance

References

Publication year

Total number of DCIS lesions included

Size HER2- DCIS

(mm)

Size HER2 + DCIS

(mm)

Reported p value (univariate analysis)

Van Bockstal et al. [22]

2014

89

30.9 ± 34.6

29.6 ± 23.8

0.544

Borgquist et al. [7]

2015

409

22.8% of DCIS > 25 mm

38.7% of DCIS > 25 mm

0.002

Williams et al. [20]

2015

314

Lum A: 15.8

TN: 15.0

HR + : 20.0

HR-: 24.5

0.005

Miligy et al. [23]

2019

646

119 (23%) are larger than 40 mm

47 (37%) are larger than 40 mm

 < 0.0001

Thorat et al. [12]

2021

713

Median size HER2 IHC 0/1 + : 13.8 mm

Median size HER2 IHC 2 + : 13.5 mm

Median size: 16 mm

0.0001

O’Keefe et al. [11]

2021

1540

26% of DCIS is > 15 mm

33% of DCIS is > 15 mm

0.0142

Yang et al. [24]

2022

5.628

72% of DCIS is < 16 mm

64% of DCIS is < 16 mm

 < 0.001

  1. DCIS ductal carcinoma in situ, HR hormone receptor, lum luminal, neg negative, pos positive, TN triple negative